Schrödinger is a scientific leader in computational drug design for pharmaceutical and biotechnology research

Schrödinger makes significant investments in R&D, which has led to major advances in the field of computational chemistry. Working closely with its scientific advisory board – a distinguished group of leading academic and industrial scientists who collectively have over one thousand publications with over 50,000 citations – Schrödinger has achieved breakthroughs in quantum chemistry, molecular modeling, force fields, molecular dynamics, protein structure determination, and docking. Schrödinger's methods development and applications papers have over one thousand citations and are often among the most-cited scientific publications. Schrödinger's science is extensively validated by its growing legion of loyal users.

Schrödinger is driven by the belief that advanced computational techniques will be an increasingly critical component of the way chemists design molecules. Today, the predictive power of Schrödinger's software allows scientists to accelerate their research and development activities, reduce research costs, and make novel discoveries that might otherwise not be possible.

The company's full product offerings range from general molecular modeling programs to a comprehensive suite of drug design software including both ligand- and structure‑based methods. Most recently, Schrödinger acquired the Seurat platform to add enterprise-wide data sharing and visualization to its complete offerings. Founded in 1990, Schrödinger has operations in several locations within the United States as well as in Europe, India, and Japan. Schrödinger's customers include nearly all the top 50 global pharmaceutical companies, hundreds more pharmaceutical and biotech companies, and numerous universities, non-profit institutions, and governmental agencies, including supercomputing centers.